LYMPHOMA, T-CELL, PERIPHERAL
Clinical trials for LYMPHOMA, T-CELL, PERIPHERAL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL, PERIPHERAL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, PERIPHERAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare blood cancer: experimental drug faces final test
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard treatments for people with a rare blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior therapy. About 150 adults will be randomly assigned to receive either soquelitinib or a standar…
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New hope for rare blood cancer: drug combo aims to keep patients in remission longer
Disease control Recruiting nowThis study tests whether adding the drug tucidinostat to standard chemotherapy (CHOP) can help people with a rare type of lymphoma (PTCL-TFH) live longer without their cancer growing or coming back. About 224 adults newly diagnosed with this disease will receive either tucidinost…
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC